The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
iwCLL 2017 | Can BCR inhibitors be used to treat all CLL patients or only a subset?
Javier Pinilla-Ibarz, MD, PhD, from H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, discusses the use of B-cell receptor (BCR) inhibitors, namely PI3K inhibitors and BTK inhibitors, in treating chronic lymphocytic leukemia (CLL) and their differing effects in different subsets of patients, which presents a concern. This video was recorded at the International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2017 in New York, NY.
